Skip to main content

The evolving role of lab collaborations in healthcare

In an increasingly complex healthcare environment, the critical integration of laboratory services across health systems is more vital than ever. In a recent podcast from the American College of Health Executives, Dr Yuri Fesko, Senior Vice President and Chief Medical Officer of Quest Diagnostics, outlined how lab partnerships extend far beyond mere transactional relationships. In other words, when aimed at driving efficiency, improving patient care, and ultimately enhancing the financial health of healthcare systems, lab collaborations can be powerfully strategic. 

Analytics and scalability: Key considerations in lab collaborations

When evaluating potential lab partners, healthcare executives need to answer a number of challenging questions. Among  those is whether a lab can provide the analytics a healthcare system requires. “Is a lab going to be able to provide the analytics that a health system is going to need?” Typically, health systems may have multiple hospitals and various lab information systems due to acquisitions over time. This fragmentation can pose significant challenges in delivering personalized, consistent patient care.

Dr. Fesko describes how Quest Diagnostics offers robust analytics that can ensure informed decision-making across a healthcare network. By focusing on gaps in care and providing data-driven insights, an effective lab affiliation can help healthcare executives meet their strategic goals and provide the necessary infrastructure to coordinate care across different settings, ultimately helping to enhance patient outcomes.

Financial pressures and cost-effectiveness: The value proposition of lab collaborations

One of the pressing issues in healthcare today is the relentless financial pressures on health systems. In this context, Dr. Fesko emphasizes how strategic lab collaborations are critical to improving cost-effectiveness. He mentions, “Partnering with a large lab like Quest Diagnostics can provide… preferred relationships with a lot of the vendors across the country.” This aligns with Quest's ability to negotiate cost savings on instruments and reagents due to its size and competitive position in the marketplace.

The reduction of operational costs can significantly help enhance a health system’s profitability and productivity. As Dr. Fesko notes, “By doing that, we can also help with best practices in terms of automation.” The introduction of automation and innovative technologies within lab operations can help minimize labor costs and enhance efficiency.

By aiming for cost-effective solutions through collaborative innovation, healthcare executives can respond to the increasing challenges in delivering high-quality, affordable care.

The future of laboratory services: A vision for integration

The future of lab services is becoming more complex. Dr. Fesko provides examples of an observable shift toward delivering care outside traditional hospital environments, sparking changes in laboratory operations. “There's more complexity to the laboratory testing that's performed, and there's a lot more strategy [toward] meeting the patient where they are.” This trend toward outpatient care necessitates a reevaluation of how labs integrate with healthcare settings.

With the advent of technologies like mobile phlebotomy and point-of-care devices, labs also need to expand patient access and address the unique needs of at-risk patient segments. The emphasis will be on providing accessible, timely testing while ensuring a seamless integration with health systems. 

Dr. Fesko also highlights the importance of being proactive in innovating: “If you're trying to do it all on your own, it's difficult. Just keeping up with the latest medical advances can be overwhelming, even without considering rapidly changing technology, market conditions, and public health trends.” To remain agile and effective in the face of rising complexity, health systems will increasingly rely on collaborations to navigate new challenges and optimize patient care.

Listen to the entire

podcast episode

Listen here

Disclaimer: "The use of the term lab partnership or partnerships does not imply the existence of a legal business entity and employees of the entities are not joint employees.”

Yuri Fesko, M.D.

Senior Vice President & Chief Medical Officer

Yuri Fesko, M.D., is Senior Vice President and Chief Medical Officer (CMO) of Quest Diagnostics. He assumed the role of CMO in December 2023. 

As CMO, Dr. Fesko is responsible for overseeing medical affairs, including clinical development and health plan policy support for new services and care delivery models. He also leads scientific communications for the company’s medical team of approximately 600 M.D.s and Ph.D.s. 

Since joining Quest in 2016, Dr. Fesko has held several roles of increasing responsibility, most recently as Vice President of Medical Affairs and Senior Medical Director for the company’s oncology services. 

Board certified in oncology, hematology and internal medicine, Dr. Fesko led clinical development of several innovations for Quest, including the company’s 500 gene somatic tumor next-generation sequencing panel as well as the company’s decentralized clinical trials model. He also pioneered the company’s precision pathways model of care, which helps oncologists and pathologists at health systems speed guideline-based biomarker testing for advanced cancers. In addition, he led clinical research on the minimal residual disease (MRD) test technology developed by Haystack Oncology, informing Quest’s decision to acquire the company in 2023 to establish a position in cancer recurrence testing. 

Prior to joining Quest, Dr. Fesko was medical director of oncology for Duke Cancer Center in Raleigh, N.C., where he focused on genitourinary oncology and multiple myeloma, and was chief of oncology for Wake County, N.C. Dr. Fesko completed his fellowship in hematology and oncology and earned his medical and bachelor's degrees from Case Western Reserve University in Cleveland. He is author of multiple peer reviewed publications.